Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Spark Therapeutics, Inc. (ONCE)
|
Add to portfolio |
|
|
|
| Price: |
$113.57
| | Metrics |
| OS: |
38.5
|
M
| |
-72
|
% ROE
|
| Market cap: |
$4.38
|
B
| |
-60
|
% ROIC
|
|
Net cash:
|
$381
|
M
| |
$9.88
|
per share
|
|
EV:
|
$3.99
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($240)
|
M
| |
|
|
|
EBIT
|
($250)
|
M
| |
|
|
| EPS |
($6.56)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 64.7 | 12.1 | 20.2 | 22.1 | 0.6 |
| Revenue growth | 436.4% | -40.2% | -8.5% | 3380.4% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 64.7 | 12.1 | 20.2 | 22.1 | 0.6 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research and development | 125.3 | 135.2 | 86.4 | 46.0 | 16.4 |
| General and administrative | 124.9 | 111.1 | 48.1 | 23.4 | 7.9 |
| EBIT | -193.3 | -234.2 | -114.3 | -47.3 | -23.6 |
| EBIT margin | -298.7% | -1941.1% | -566.2% | -214.5% | -3719.7% |
| Pre-tax income | -78.8 | -253.5 | -123.7 | -47.1 | -24.3 |
| Income taxes | -0.1 | 1.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.1% | | 0.0% | 0.0% | 0.0% |
| Net income | -78.7 | -254.4 | -123.7 | -47.8 | -25.0 |
| Net margin | -121.6% | -2108.8% | -612.7% | -216.5% | -3948.7% |
| |
| Diluted EPS | ($2.11) | ($7.65) | ($4.29) | ($2.10) | ($4.64) |
| Shares outstanding (diluted) | 37.4 | 33.2 | 28.8 | 22.7 | 5.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|